CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
OculusGen Biodegradable Collagen Matrix Implantdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00448929
NCT00448929Phase 3Completed
CompareCT.gov

Comparative Study of the Safety and Effectiveness Between Trabeculectomy and Trabeculectomy With Ologen (OculusGen) Collagen Matrix Implant

Pro Top & Mediking Company Limited·interventional·Posted Mar 19, 2007·Updated Jun 27, 2017

In Brief

A Phase 3 clinical trial evaluating OculusGen Biodegradable Collagen Matrix Implant for Glaucoma. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the safety and effectiveness of trabeculectomy with ologen (OculusGen) Biodegradable Collagen Matrix Implant and trabeculectomy without antifibrotic agents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesIndia
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 19, 2007
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.3 years ago

Interventions

OculusGen Biodegradable Collagen Matrix Implantdevice

Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant